Tirdzniecība Roche Holding AG - ROGz CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 1.1 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.014885% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.007337% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | CHF | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | Switzerland | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Roche Holding AG ESG Risk Ratings
High Medium Low Negligible
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 291.8 |
| Atvērt* | 291.4 |
| Izmaiņas par 1 gadu* | -9.16% |
| Dienas Diapazons* | 289.1 - 291.5 |
| 52 ned Diapazons | 256.05-335.85 |
| Vidējais apjoms (10 dienas) | 1.58M |
| Vidējais apjoms (3 mēneši) | 28.15M |
| Tirgus Kapitalizācija | 238.76B |
| Cenas/Peļņas Attiecība | 19.02 |
| Izvietotās Akcijas | 799.18M |
| Ieņēmumi | 63.28B |
| EPS | 15.36 |
| Dividende (Ienesīgums %) | 3.25175 |
| Beta | 0.75 |
| Nākamās Peļņas Datums | Jul 27, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Jun 6, 2023 | 291.8 | 1.0 | 0.34% | 290.8 | 292.5 | 289.7 |
| Jun 5, 2023 | 291.7 | -1.0 | -0.34% | 292.7 | 293.0 | 291.1 |
| Jun 2, 2023 | 292.1 | 3.1 | 1.07% | 289.0 | 292.3 | 287.9 |
| Jun 1, 2023 | 288.6 | 0.6 | 0.21% | 288.0 | 290.0 | 286.8 |
| May 31, 2023 | 284.1 | -5.0 | -1.73% | 289.1 | 290.6 | 280.8 |
| May 30, 2023 | 288.2 | -0.9 | -0.31% | 289.1 | 290.2 | 286.7 |
| May 26, 2023 | 290.7 | 1.6 | 0.55% | 289.1 | 291.2 | 286.7 |
| May 25, 2023 | 287.4 | 0.8 | 0.28% | 286.6 | 288.7 | 285.9 |
| May 24, 2023 | 288.2 | 1.2 | 0.42% | 287.0 | 288.8 | 286.3 |
| May 23, 2023 | 285.8 | 0.4 | 0.14% | 285.4 | 287.8 | 284.5 |
| May 22, 2023 | 285.7 | -1.8 | -0.63% | 287.5 | 288.4 | 283.9 |
| May 19, 2023 | 287.1 | 2.1 | 0.74% | 285.0 | 288.7 | 283.9 |
| May 17, 2023 | 283.5 | 1.4 | 0.50% | 282.1 | 284.5 | 281.9 |
| May 16, 2023 | 281.6 | -1.7 | -0.60% | 283.3 | 284.0 | 280.8 |
| May 15, 2023 | 284.2 | -0.7 | -0.25% | 284.9 | 285.5 | 283.1 |
| May 12, 2023 | 283.9 | 2.0 | 0.71% | 281.9 | 284.9 | 281.9 |
| May 11, 2023 | 281.5 | 1.0 | 0.36% | 280.5 | 283.1 | 280.4 |
| May 10, 2023 | 280.2 | -1.8 | -0.64% | 282.0 | 282.0 | 278.8 |
| May 9, 2023 | 282.9 | -1.1 | -0.39% | 284.0 | 284.5 | 281.0 |
| May 8, 2023 | 283.7 | 0.3 | 0.11% | 283.4 | 285.0 | 282.8 |
Roche Holding AG Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| Thursday, June 8, 2023 | ||
| Laiks (UTC) (UTC) 06:00 | Valsts CH
| Notikums Roche Holding AG at Exane CEO Conference Roche Holding AG at Exane CEO ConferenceForecast -Previous - |
| Monday, June 12, 2023 | ||
| Laiks (UTC) (UTC) 14:30 | Valsts CH
| Notikums Roche Holding AG Virtual EHA 2023 Event: Crovalimab in Hematology and Nephrology Roche Holding AG Virtual EHA 2023 Event: Crovalimab in Hematology and NephrologyForecast -Previous - |
| Wednesday, June 14, 2023 | ||
| Laiks (UTC) (UTC) 12:00 | Valsts CH
| Notikums Roche Holding AG at Stifel Swiss Equities Conference Roche Holding AG at Stifel Swiss Equities ConferenceForecast -Previous - |
| Laiks (UTC) (UTC) 15:00 | Valsts CH
| Notikums Roche Holding AG at Goldman Sachs Healthcare Conference Roche Holding AG at Goldman Sachs Healthcare ConferenceForecast -Previous - |
| Tuesday, June 20, 2023 | ||
| Laiks (UTC) (UTC) 07:00 | Valsts CH
| Notikums Roche Holding AG at Citi European Healthcare Conference Roche Holding AG at Citi European Healthcare ConferenceForecast -Previous - |
| Wednesday, June 21, 2023 | ||
| Laiks (UTC) (UTC) 08:00 | Valsts CH
| Notikums Roche Holding AG at Deutsche Bank dbAccess German Swiss Austrian Conference Roche Holding AG at Deutsche Bank dbAccess German Swiss Austrian ConferenceForecast -Previous - |
| Thursday, June 22, 2023 | ||
| Laiks (UTC) (UTC) 07:00 | Valsts CH
| Notikums Roche Holding AG at JPMorgan European Healthcare Conference Roche Holding AG at JPMorgan European Healthcare ConferenceForecast -Previous - |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 63281 | 62801 | 58323 | 61466 | 56846 |
| Ienākumi | 63281 | 62801 | 58323 | 61466 | 56846 |
| Cost of Revenue, Total | 18511 | 19348 | 15900 | 17377 | 16445 |
| Bruto Peļņa | 44770 | 43453 | 42423 | 44089 | 40401 |
| Kopējie Darbības Izdevumi | 45805 | 44646 | 39780 | 43918 | 42077 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 12124 | 12100 | 12075 | 13208 | 12453 |
| Pētniecība un Attīstība | 14050 | 13707 | 12151 | 11690 | 11048 |
| Depreciation / Amortization | 378 | 351 | 446 | 268 | 183 |
| Neparedzēti Izdevumi (Ienākumi) | 2569 | 376 | 426 | 2677 | 3945 |
| Other Operating Expenses, Total | -1827 | -1236 | -1218 | -1302 | -1997 |
| Darbības Izdevumi | 17476 | 18155 | 18543 | 17548 | 14769 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -1040 | -677 | -463 | -758 | -419 |
| Citi, Neto | -109 | -80 | -115 | -176 | -202 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 16327 | 17398 | 17965 | 16614 | 14148 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 13531 | 14935 | 15068 | 14108 | 10830 |
| Mazākuma Interese | -1110 | -1005 | -773 | -611 | -365 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 12421 | 13930 | 14295 | 13497 | 10465 |
| Neto Ienākumi | 12421 | 13930 | 14295 | 13497 | 10500 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 12421 | 13930 | 14295 | 13497 | 10465 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 12421 | 13930 | 14295 | 13497 | 10500 |
| Atšķaidīšanas Iestāstīšana | -1 | -1 | -1 | -2 | -1 |
| Atšķaidītie Neto Ienākumi | 12420 | 13929 | 14294 | 13495 | 10499 |
| Atšķaidītie Ienākumi par Akcijām | 808 | 860 | 865 | 864 | 860 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 15.3713 | 16.1965 | 16.5249 | 15.6192 | 12.1674 |
| Dividends per Share - Common Stock Primary Issue | 9.5 | 9.3 | 9.1 | 9 | 8.7 |
| Atšķaidītā Normalizētā Peļņa par Akciju | 17.9847 | 16.5778 | 16.9515 | 18.2807 | 15.702 |
| Ārkārtas Posteņi Kopā | 35 |
| Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
|---|---|---|---|---|
| Kopējie ienākumi | 30986 | 32295 | 32088 | 30713 |
| Ienākumi | 30986 | 32295 | 32088 | 30713 |
| Cost of Revenue, Total | 8949 | 9562 | 10279 | 9069 |
| Bruto Peļņa | 22037 | 22733 | 21809 | 21644 |
| Kopējie Darbības Izdevumi | 25057 | 20748 | 24010 | 20636 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 6479 | 5645 | 6544 | 5556 |
| Pētniecība un Attīstība | 7422 | 6628 | 7017 | 6690 |
| Depreciation / Amortization | 196 | 182 | 177 | 174 |
| Neparedzēti Izdevumi (Ienākumi) | 2584 | -15 | 619 | -243 |
| Other Operating Expenses, Total | -573 | -1254 | -626 | -610 |
| Darbības Izdevumi | 5929 | 11547 | 8078 | 10077 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -568 | -472 | -524 | -151 |
| Citi, Neto | -19 | -90 | -43 | -39 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 5342 | 10985 | 7511 | 9887 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 4370 | 9161 | 6719 | 8216 |
| Mazākuma Interese | -479 | -631 | -592 | -413 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 3891 | 8530 | 6127 | 7803 |
| Neto Ienākumi | 3891 | 8530 | 6127 | 7803 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 3891 | 8530 | 6127 | 7803 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 3891 | 8530 | 6127 | 7803 |
| Atšķaidīšanas Iestāstīšana | -1 | 0 | -1 | 0 |
| Atšķaidītie Neto Ienākumi | 3890 | 8530 | 6126 | 7803 |
| Atšķaidītie Ienākumi par Akcijām | 806 | 810 | 858 | 862 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 4.8263 | 10.5309 | 7.13986 | 9.0522 |
| Dividends per Share - Common Stock Primary Issue | 9.5 | 0 | 9.3 | 0 |
| Atšķaidītā Normalizētā Peļņa par Akciju | 7.42355 | 10.5195 | 7.78732 | 8.8218 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 33816 | 35627 | 32942 | 31254 | 32244 |
| Nauda un Īstermiņa Ieguldījumi | 9767 | 13031 | 12334 | 11858 | 13118 |
| Cash | 2841 | 5028 | 4536 | 4769 | 4139 |
| Nauda un Ekvivalenti | 2150 | 1822 | 1191 | 1306 | 2542 |
| Īstermiņa Ieguldījumi | 4776 | 6181 | 6607 | 5783 | 6437 |
| Debitoru Parādu Kopsumma, Neto | 13866 | 12651 | 11740 | 12150 | 11487 |
| Accounts Receivable - Trade, Net | 11527 | 10719 | 10056 | 10343 | 9687 |
| Total Inventory | 8605 | 7715 | 7194 | 6055 | 6621 |
| Prepaid Expenses | 1202 | 1869 | 1153 | 795 | 683 |
| Other Current Assets, Total | 376 | 361 | 521 | 396 | 335 |
| Total Assets | 88151 | 92317 | 86138 | 83091 | 78517 |
| Property/Plant/Equipment, Total - Net | 24208 | 24412 | 23270 | 23318 | 21818 |
| Property/Plant/Equipment, Total - Gross | 49408 | 48205 | 45664 | 45041 | 41822 |
| Accumulated Depreciation, Total | -25200 | -23793 | -22394 | -21723 | -20004 |
| Goodwill, Net | 10820 | 10809 | 9249 | 12456 | 8948 |
| Intangibles, Net | 9685 | 12117 | 12017 | 8358 | 9346 |
| Long Term Investments | 971 | 1069 | 1276 | 739 | 602 |
| Note Receivable - Long Term | 125 | 133 | 125 | 128 | 132 |
| Other Long Term Assets, Total | 8526 | 8150 | 7259 | 6838 | 5427 |
| Total Current Liabilities | 27239 | 38416 | 25401 | 24119 | 23033 |
| Accounts Payable | 3861 | 3844 | 3317 | 3176 | 2847 |
| Accrued Expenses | 12180 | 12497 | 11205 | 11214 | 10676 |
| Notes Payable/Short Term Debt | 2191 | 14618 | 2189 | 1694 | 722 |
| Current Port. of LT Debt/Capital Leases | 2071 | 833 | 2126 | 341 | 1971 |
| Other Current Liabilities, Total | 6936 | 6624 | 6564 | 7694 | 6817 |
| Total Liabilities | 60159 | 67828 | 49797 | 50344 | 50895 |
| Total Long Term Debt | 22282 | 17101 | 11096 | 13547 | 16077 |
| Long Term Debt | 21391 | 16076 | 10220 | 12668 | 16075 |
| Capital Lease Obligations | 891 | 1025 | 876 | 879 | 2 |
| Deferred Income Tax | 645 | 628 | 353 | 298 | 384 |
| Minority Interest | 4023 | 3856 | 3432 | 3120 | 2744 |
| Other Liabilities, Total | 5970 | 7827 | 9515 | 9260 | 8657 |
| Total Equity | 27992 | 24489 | 36341 | 32747 | 27622 |
| Common Stock | 107 | 160 | 160 | 160 | 160 |
| Retained Earnings (Accumulated Deficit) | 38937 | 34161 | 45571 | 40524 | 34935 |
| Unrealized Gain (Loss) | -59 | -60 | 106 | 15 | 28 |
| Other Equity, Total | -10993 | -9772 | -9496 | -7952 | -7501 |
| Total Liabilities & Shareholders’ Equity | 88151 | 92317 | 86138 | 83091 | 78517 |
| Total Common Shares Outstanding | 799.181 | 800.403 | 853.126 | 855.756 | 854.428 |
| Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 33816 | 30321 | 35627 | 31260 |
| Nauda un Īstermiņa Ieguldījumi | 9767 | 6808 | 13031 | 8017 |
| Nauda un Ekvivalenti | 4991 | 4315 | 6850 | 5000 |
| Īstermiņa Ieguldījumi | 4776 | 2493 | 6181 | 3017 |
| Debitoru Parādu Kopsumma, Neto | 11919 | 11078 | 11126 | 11809 |
| Accounts Receivable - Trade, Net | 11606 | 10809 | 10806 | 11656 |
| Total Inventory | 8605 | 8292 | 7715 | 8319 |
| Other Current Assets, Total | 3525 | 4143 | 3755 | 3115 |
| Total Assets | 88151 | 86736 | 92317 | 87887 |
| Property/Plant/Equipment, Total - Net | 24208 | 24324 | 24412 | 24300 |
| Goodwill, Net | 10820 | 11160 | 10809 | 10623 |
| Intangibles, Net | 9685 | 11735 | 12117 | 12510 |
| Other Long Term Assets, Total | 9622 | 9196 | 9352 | 9194 |
| Total Current Liabilities | 27239 | 27409 | 38416 | 25193 |
| Payable/Accrued | 4556 | 3896 | 4637 | 4241 |
| Notes Payable/Short Term Debt | 2191 | 2976 | 14618 | 2530 |
| Current Port. of LT Debt/Capital Leases | 1769 | 2405 | 504 | 1196 |
| Other Current Liabilities, Total | 18723 | 18132 | 18657 | 17226 |
| Total Liabilities | 60159 | 61547 | 67828 | 50073 |
| Total Long Term Debt | 21391 | 22369 | 16076 | 11285 |
| Long Term Debt | 21391 | 22369 | 16076 | 11285 |
| Deferred Income Tax | 645 | 690 | 628 | 499 |
| Minority Interest | 4023 | 3757 | 3856 | 3619 |
| Other Liabilities, Total | 6861 | 7322 | 8852 | 9477 |
| Total Equity | 27992 | 25189 | 24489 | 37814 |
| Common Stock | 107 | 107 | 160 | 160 |
| Retained Earnings (Accumulated Deficit) | 38937 | 35740 | 34161 | 46686 |
| Unrealized Gain (Loss) | -59 | -151 | -60 | -90 |
| Other Equity, Total | -10993 | -10507 | -9772 | -8942 |
| Total Liabilities & Shareholders’ Equity | 88151 | 86736 | 92317 | 87887 |
| Total Common Shares Outstanding | 799.181 | 800.579 | 800.403 | 854.261 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | 13531 | 14935 | 15068 | 14108 | 10865 |
| Nauda no Darbības | 18415 | 20976 | 18566 | 22385 | 19979 |
| Nauda no Darbības | 2906 | 2887 | 2808 | 2760 | 2292 |
| Amortization | 938 | 1556 | 1750 | 1532 | 1294 |
| Bezskaidras Naudas Preces | 9267 | 7718 | 6227 | 8883 | 10308 |
| Cash Taxes Paid | 4102 | 3343 | 3236 | 3543 | 3288 |
| Samaksātie Procenti Naudā | 557 | 407 | 422 | 624 | 593 |
| Izmaiņas Apgrozāmajā Kapitālā | -8227 | -6120 | -7287 | -4898 | -4780 |
| Nauda no Ieguldījumu Darbībām | -3536 | -6552 | -9067 | -8634 | -7195 |
| Kapitālie Izdevumi | -4797 | -4652 | -7858 | -4896 | -6746 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 1261 | -1900 | -1209 | -3738 | -449 |
| Nauda no Darbībām ar Finansēšanu | -16275 | -13108 | -9666 | -14173 | -10691 |
| Naudas Plūsma Finansēšanas Posteņos | -2340 | -2333 | -1992 | -1716 | -3316 |
| Total Cash Dividends Paid | -7832 | -8132 | -7964 | -7682 | -7253 |
| Parādu Izsniegšana (Atkāpšanās), Neto | -6103 | 16348 | 290 | -4775 | -122 |
| Ārvalstu Valūtas Ietekme | -463 | -193 | -181 | -184 | -131 |
| Neto Izmaiņas Naudā | -1859 | 1123 | -348 | -606 | 1962 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 0 | -18991 |
| Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
|---|---|---|---|---|
| Net income/Starting Line | 13531 | 9161 | 14935 | 8216 |
| Cash From Operating Activities | 18415 | 9509 | 20976 | 8212 |
| Cash From Operating Activities | 2906 | 1429 | 2887 | 1439 |
| Amortization | 938 | 471 | 1556 | 830 |
| Non-Cash Items | 9267 | 3799 | 7718 | 3323 |
| Cash Taxes Paid | 4102 | 2482 | 3343 | 2183 |
| Cash Interest Paid | 557 | 228 | 407 | 243 |
| Changes in Working Capital | -8227 | -5351 | -6120 | -5596 |
| Cash From Investing Activities | -3536 | 1473 | -6552 | 44 |
| Capital Expenditures | -4797 | -2067 | -4652 | -2197 |
| Other Investing Cash Flow Items, Total | 1261 | 3540 | -1900 | 2241 |
| Cash From Financing Activities | -16275 | -13315 | -13108 | -9056 |
| Financing Cash Flow Items | -2340 | -1374 | -2333 | -1211 |
| Total Cash Dividends Paid | -7832 | -7672 | -8132 | -7955 |
| Issuance (Retirement) of Debt, Net | -6103 | -4269 | 16348 | 110 |
| Foreign Exchange Effects | -463 | -202 | -193 | 73 |
| Net Change in Cash | -1859 | -2535 | 1123 | -727 |
| Issuance (Retirement) of Stock, Net | 0 | -18991 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.1087 | 21840391 | 178848 | 2023-04-30 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.8532 | 20045265 | 2208289 | 2022-12-31 | LOW |
| UBS Asset Management (Switzerland) | Investment Advisor | 1.8605 | 13071428 | -39477 | 2023-04-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.8324 | 12873933 | 77580 | 2023-04-30 | LOW |
| Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 1.6652 | 11699069 | 7778 | 2023-04-30 | LOW |
| MFS Investment Management | Investment Advisor/Hedge Fund | 1.5324 | 10765987 | 125180 | 2023-04-30 | LOW |
| Zürcher Kantonalbank (Asset Management) | Bank and Trust | 1.239 | 8704542 | 83328 | 2023-04-30 | LOW |
| BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.999 | 7018571 | -33622 | 2023-04-30 | LOW |
| Fidelity International | Investment Advisor | 0.8386 | 5891865 | 51949 | 2023-04-30 | LOW |
| DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.6723 | 4723312 | 9296 | 2023-04-30 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.6582 | 4624038 | 664 | 2023-04-30 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 0.6079 | 4271039 | 22563 | 2023-04-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6058 | 4256225 | 28940 | 2023-04-30 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 0.5908 | 4150400 | 75100 | 2023-03-31 | LOW |
| California Public Employees' Retirement System | Pension Fund | 0.5839 | 4102151 | -453583 | 2022-06-30 | LOW |
| Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.4934 | 3466391 | -1771057 | 2023-04-30 | MED |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.4679 | 3287387 | -5027 | 2023-04-30 | LOW |
| RBC Global Asset Management (UK) Limited | Investment Advisor | 0.4129 | 2900866 | -94725 | 2023-04-30 | LOW |
| PRIMECAP Management Company | Investment Advisor | 0.3704 | 2602358 | -25668 | 2023-03-31 | LOW |
| Mawer Investment Management Ltd. | Investment Advisor | 0.3591 | 2522750 | 3313 | 2023-03-31 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group535K+
Tirgotāji
87K+
Ikmēneša aktīvie klienti
$113M+
Ikmēneša ieguldījumu apjoms
$64M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Roche Company profile
Par Roche Holding AG
Roche Holding AG ("Roche") ir uz pētniecību balstīts veselības aprūpes uzņēmums. Uzņēmuma pamatdarbība ir organizēta divās nodaļās: Farmaceitiskie līdzekļi un Diagnostika. Farmaceitisko līdzekļu nodaļa sastāv no diviem uzņēmējdarbības segmentiem: Roche Pharmaceuticals un Chugai. Diagnostikas nodaļu veido četras uzņēmējdarbības jomas: Diabēta aprūpe, Molekulārā diagnostika, Profesionālā diagnostika un Audu diagnostika. Uzņēmums izstrādā zāles dažādām slimību jomām, tostarp onkoloģijai, imunoloģijai, infekcijas slimībām, oftalmoloģijai un neiroloģijai. Tās farmācijas produktu vidū ir Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin un Roferon-A. Uzņēmums piedāvā produktus pētniekiem, tostarp šūnu analīzes, gēnu ekspresijas, genoma sekvencēšanas un nukleīnskābju attīrīšanas jomā.
| Industry: | Pharmaceuticals (NEC) |
Grenzacherstrasse 124
BASEL
BASEL-STADT 4058
CH
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 535 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com